Literature DB >> 24444773

The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis.

Sumeda Nandadasa1, Simon Foulcer1, Suneel S Apte2.   

Abstract

Embryonic development is an exceptionally dynamic process, requiring a provisional extracellular matrix that is amenable to rapid remodeling, and proteolytic or non-proteolytic mechanisms that can remodel the major components of this matrix. Versican is a chondroitin-sulfate proteoglycan that forms highly hydrated complexes with hyaluronan and is widely distributed in the provisional matrix of mammalian embryos. It has been extensively studied in the context of cardiovascular morphogenesis, neural crest cell migration and skeletal development. Analysis of Vcan transgenic mice has established the requirement for versican in cardiac development and its role in skeletogenesis. The ADAMTS family includes several versican-degrading proteases that are active during remodeling of the embryonic provisional matrix, especially during sculpting of versican-rich tissues. Versican is cleaved at specific peptide bonds by ADAMTS proteases, and the cleavage products are detectable by neo-epitope antibodies. Myocardial compaction, closure of the secondary palate (in which neural crest derived cells participate), endocardial cushion remodeling, myogenesis and interdigital web regression are developmental contexts in which ADAMTS-mediated versican proteolysis has been identified as a crucial requirement. ADAMTS proteases are expressed coordinately and function cooperatively in many of these contexts. In addition to versican clearance, ADAMTS proteases generate a bioactive versican fragment containing the N-terminal G1 domain, which we have named versikine. This review promotes the view that the embryonic extracellular matrix has evolved not only to provide a permissive environment for embryo growth and morphogenesis, but through its dissolution to influence and regulate cellular processes.
Copyright © 2014 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  A disintegrin-like and metalloprotease domain with thrombospondin type 1 motifs; ADAMTS; Cardiac jelly; Cleft palate; Embryogenesis; Heart valve; Limb development; Melanoblast; Soft tissue syndactyly; Versican

Mesh:

Substances:

Year:  2014        PMID: 24444773      PMCID: PMC5525047          DOI: 10.1016/j.matbio.2014.01.005

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  84 in total

1.  Histochemical localisation of versican, aggrecan and hyaluronan in the developing condylar cartilage of the fetal rat mandible.

Authors:  S Shibata; K Fukada; S Suzuki; T Ogawa; Y Yamashita
Journal:  J Anat       Date:  2001-02       Impact factor: 2.610

2.  Collagenolytic activity in amphibian tissues: a tissue culture assay.

Authors:  J GROSS; C M LAPIERE
Journal:  Proc Natl Acad Sci U S A       Date:  1962-06-15       Impact factor: 11.205

Review 3.  Extracellular matrix of the central nervous system: from neglect to challenge.

Authors:  Dieter R Zimmermann; María T Dours-Zimmermann
Journal:  Histochem Cell Biol       Date:  2008-08-12       Impact factor: 4.304

4.  Clinical characterisation and molecular analysis of Wagner syndrome.

Authors:  Sarah P Meredith; Allan J Richards; Declan W Flanagan; John D Scott; Arabella V Poulson; Martin P Snead
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

5.  Versican facilitates chondrocyte differentiation and regulates joint morphogenesis.

Authors:  Kanyamas Choocheep; Sonoko Hatano; Hidekazu Takagi; Hiroki Watanabe; Koji Kimata; Prachya Kongtawelert; Hideto Watanabe
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

6.  Limb chondrogenesis is compromised in the versican deficient hdf mouse.

Authors:  Dennis R Williams; Ashley R Presar; A Todd Richmond; Corey H Mjaatvedt; Stanley Hoffman; Anthony A Capehart
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

7.  Mapping of the versican proteoglycan gene (CSPG2) to the long arm of human chromosome 5 (5q12-5q14).

Authors:  R V Iozzo; M F Naso; L A Cannizzaro; J J Wasmuth; J D McPherson
Journal:  Genomics       Date:  1992-12       Impact factor: 5.736

8.  Expression pattern and mapping of the murine versican gene (Cspg2) to chromosome 13.

Authors:  M F Naso; J L Morgan; A M Buchberg; L D Siracusa; R V Iozzo
Journal:  Genomics       Date:  1995-09-01       Impact factor: 5.736

9.  A large chondroitin sulfate proteoglycan (PG-M) synthesized before chondrogenesis in the limb bud of chick embryo.

Authors:  K Kimata; Y Oike; K Tani; T Shinomura; M Yamagata; M Uritani; S Suzuki
Journal:  J Biol Chem       Date:  1986-10-15       Impact factor: 5.157

10.  Pathways of trunk neural crest cell migration in the mouse embryo as revealed by vital dye labelling.

Authors:  G N Serbedzija; S E Fraser; M Bronner-Fraser
Journal:  Development       Date:  1990-04       Impact factor: 6.868

View more
  65 in total

1.  A new Adamts9 conditional mouse allele identifies its non-redundant role in interdigital web regression.

Authors:  Johanne Dubail; Noriko Aramaki-Hattori; Hannah L Bader; Courtney M Nelson; Negin Katebi; Brittany Matuska; Bjorn R Olsen; Suneel S Apte
Journal:  Genesis       Date:  2014-05-08       Impact factor: 2.487

2.  Partially Digested Adult Cardiac Extracellular Matrix Promotes Cardiomyocyte Proliferation In Vitro.

Authors:  Corin Williams; Kelly Sullivan; Lauren D Black
Journal:  Adv Healthc Mater       Date:  2015-05-18       Impact factor: 9.933

3.  Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.

Authors:  Chelsea Hope; Philip B Emmerich; Athanasios Papadas; Adam Pagenkopf; Kristina A Matkowskyj; Dana R Van De Hey; Susan N Payne; Linda Clipson; Natalie S Callander; Peiman Hematti; Shigeki Miyamoto; Michael G Johnson; Dustin A Deming; Fotis Asimakopoulos
Journal:  J Immunol       Date:  2017-07-28       Impact factor: 5.422

4.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

5.  Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.

Authors:  Apostolos G Pappas; Sophia Magkouta; Ioannis S Pateras; Ioannis Skianis; Charalampos Moschos; Maria Eleni Vazakidou; Katherina Psarra; Vassilis G Gorgoulis; Ioannis Kalomenidis
Journal:  Oncoimmunology       Date:  2018-11-02       Impact factor: 8.110

6.  Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5.

Authors:  Simon J Foulcer; Courtney M Nelson; Maritza V Quintero; Balagurunathan Kuberan; Jonathan Larkin; Maria T Dours-Zimmermann; Dieter R Zimmermann; Suneel S Apte
Journal:  J Biol Chem       Date:  2014-08-13       Impact factor: 5.157

7.  Massive aggrecan and versican accumulation in thoracic aortic aneurysm and dissection.

Authors:  Frank S Cikach; Christopher D Koch; Timothy J Mead; Josephine Galatioto; Belinda B Willard; Kelly B Emerton; Matthew J Eagleton; Eugene H Blackstone; Francesco Ramirez; Eric E Roselli; Suneel S Apte
Journal:  JCI Insight       Date:  2018-03-08

Review 8.  Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Authors:  Inkyung Kang; Mary Y Chang; Thomas N Wight; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

9.  Correlation of Versican Expression, Accumulation, and Degradation during Embryonic Development by Quantitative Immunohistochemistry.

Authors:  Jessica M Snyder; Ida M Washington; Timothy Birkland; Mary Y Chang; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2015-09-18       Impact factor: 2.479

Review 10.  Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis.

Authors:  Suneel S Apte
Journal:  Biochem J       Date:  2016-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.